Trial results were presented at 2013 ESMO World Congress on Gastrointestinal Cancer
When compared with patients who undergo surgery only, patients with advanced gastric cancer who receive the combination chemotherapy XELOX (capecitabine and oxaliplatin) following standard D2 gastrectomy experience a reduction in cancer-related deaths over a 5-year period, according to follow-up results from the multinational phase 3 CLASSIC trial.
The study results were presented by professor Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea.
Source: 2013 ESMO World Congress on Gastrointestinal Cancer Press Release.